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Aspiration Thrombectomy*
Dharam J. Kumbhani, MD, SM,y Anthony A. Bavry, MD, MPHzSEE PAGE 126T he hallmark of ST-segment elevation myo-cardial infarction (STEMI) is thromboticocclusion of an epicardial vessel. As many
as 50% of patients undergoing primary percutaneous
coronary intervention (PCI) demonstrate distal em-
bolization and microvascular obstruction despite
achieving normalized epicardial ﬂow. This is associ-
ated with increased infarct size, reduced recovery of
ventricular function, and reduced survival (1,2). In
an effort to reduce distal embolization, a number of
thrombectomy devices have been studied for use
with primary PCI. The story of aspiration thrombec-
tomy is a sterling example of the utility of evidence-
based medicine in contemporary clinical practice,
where initial exuberance for a new therapy was
tempered by a more limited or measured application
on the basis of accrual of high-quality data. Some of
the salient features are discussed in the following
text.
THE RISE
TAPAS (Thrombus Aspiration during Percutaneous
Coronary Intervention in Acute Myocardial Infarc-
tion Study) was one of the sentinel trials in this
ﬁeld (n ¼ 1,071). At 1 year, there were signiﬁcant
reductions in all-cause (4.7% vs. 7.6%; p ¼ 0.04)
and cardiovascular (3.6% vs. 6.7%; p ¼ 0.02) mor-
tality, with a trend toward reduction in subacute
and late stent thrombosis with adjunctive aspira-
tion thrombectomy compared with conventional PCI*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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from the American College of Cardiology.alone (3). Although the trial was criticized for its
limitations (possible selection bias [single-center
study], unclear mechanism [no difference in enzy-
matic infarct size post-procedure but a signiﬁcant
difference in cardiovascular and all-cause mortality
at 1 year], and possibility of chance [trial was not
powered for mortality]), the overall clinical out-
comes were directionally consistent with other
smaller trials (2). On the basis of this data, aspira-
tion thrombectomy received a Class IIa recommen-
dation for use with PCI in the 2009 American
College of Cardiology (ACC)/ American Heart Asso-
ciation (AHA) STEMI guidelines (4).Commensurate with the timeframe of evidence
accrual, there appeared to be a gradual uptake of
aspiration thrombectomy in clinical practice the
world over. In this issue of JACC: Cardiovascular
Interventions, Sirker et al. (5) estimate that the
uptake of adjunctive thrombectomy in the United
Kingdom was around 50% by 2010 to 2011.
THE FALL
The INFUSE-AMI (Infuse–Acute Myocardial Infarc-
tion) trial failed to replicate the ﬁndings of the TAPAS
trial in 452 patients, with no differences observed in
infarct size with aspiration thrombectomy at 30 days
(6). Despite this, on systematic review, the totality
of evidence still favored a beneﬁt in clinical out-
comes with aspiration thrombectomy, particularly
on longer-term follow-up (7), and it remained a Class
IIa recommendation in the 2013 ACC/AHA STEMI
guidelines (8).
TASTE (Thrombus Aspiration in ST-Elevation
Myocardial Infarction in Scandinavia) was a large,
multicenter, registry-based randomized clinical trial
(n ¼ 7,244). There were no differences in clinical
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136outcomes assessed at 1 year between aspiration
thrombectomy versus conventional PCI, including
all-cause mortality (5.3% vs. 5.6%; p ¼ 0.57) or stent
thrombosis (0.7% vs. 0.9%; p ¼ 0.51) (9). TOTAL (Trial
of Routine Aspiration Thrombectomy with PCI versus
PCI Alone in Patients with STEMI) is the largest and
most deﬁnitive trial on this topic to date (n ¼ 10,732).
No differences in clinical outcomes were observed at
6 months in favor of aspiration thrombectomy,
including in the primary outcome of major adverse
cardiovascular events (6.9% vs. 7.0%; p ¼ 0.86), car-
diovascular death (3.1% vs. 3.5%; p ¼ 0.34), or stent
thrombosis (1.5% vs. 1.7%; p ¼ 0.42); stroke rates were
higher with aspiration thrombectomy (0.7% vs. 0.3%;
p ¼ 0.02) (10). On the basis of this evidence, routine
aspiration thrombectomy has been downgraded to a
Class III recommendation in the most recent (2015)
iteration of the ACC/AHA STEMI guidelines (11).
The current study by Sirker et al. (5) provides
further evidence against routine aspiration throm-
bectomy use during primary PCI. They included
98,176 STEMI patients undergoing primary PCI from
the U.K. national PCI registry. On propensity analysis,
there was no difference in 1-year mortality between
any form of thrombectomy versus conventional PCI,
including adjunctive aspiration thrombectomy and
conventional PCI (n ¼ 85,675; p ¼ 0.96) (5). This is an
important body of work on a large cohort of patients.
However, causative inferences regarding therapeutic
choices from observational datasets can be hard at
best, and outright wrong at worst, as unmeasured
confounders can obfuscate all and any statistical
adjustments. Physicians frequently make therapeutic
decisions on the basis of characteristics that can be
hard to capture in registries (such as frailty, “eyeball
test,” and so on). In such settings, inverse probability
of treatment weights may be a less confounded way
of performing a propensity analysis, wherein in-
dividuals are weighted by the inverse probabilityof receiving the treatment that they actually received.
In the current study, the authors chose to perform a
more conventional propensity analysis, thus being
potentially more vulnerable to selection biases.
However, the results of the current study are direc-
tionally consistent with recent randomized controlled
trials, and are thus less likely to be spurious. Coding
errors may also be present in registries. For example,
patients in this study that did not receive thrombec-
tomy were older, more frequently had diabetes, less
frequently smoked, and more frequently had pre-
procedure Thrombolysis In Myocardial Infarction 2
to 3 ﬂow. Although these patients were classiﬁed as
“STEMI,” such characteristics more closely resemble
that of non-STEMI, which carries a different prog-
nosis than STEMI. Left ventricular ejection fraction
was also missing for a large proportion of patients,
which is an important determinant of outcomes
following STEMI, and may also result in unmeasured
confounding. However, the authors performed
sensitivity analyses using both nonimputed and
imputed data for LVEF and report a similar treatment
effect (5).
In summary, routine aspiration thrombectomy was
once considered a relatively simple technique to
improve long-term outcomes in the care of STEMI
patients. Thrombus removal remains an intuitively
valid concept; however, thrombus removal is more
complex than initially appreciated. Future studies
will need to similarly rigorously evaluate the role of
selective thrombectomy versus no thrombectomy,
determine more effective thrombectomy devices,
and better discriminate appropriate lesions to which
this therapy can be applied.
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